These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24242074)

  • 61. The idebenone metabolite QS10 restores electron transfer in complex I and coenzyme Q defects.
    Giorgio V; Schiavone M; Galber C; Carini M; Da Ros T; Petronilli V; Argenton F; Carelli V; Acosta Lopez MJ; Salviati L; Prato M; Bernardi P
    Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):901-908. PubMed ID: 29694828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mitochondrial therapies for Parkinson's disease.
    Thomas B; Beal MF
    Mov Disord; 2010; 25 Suppl 1(Suppl 1):S155-60. PubMed ID: 20187246
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
    Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
    Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials.
    Lei L; Liu Y
    BMC Cardiovasc Disord; 2017 Jul; 17(1):196. PubMed ID: 28738783
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mitochondrial medicine for aging and neurodegenerative diseases.
    Reddy PH
    Neuromolecular Med; 2008; 10(4):291-315. PubMed ID: 18566920
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment for mitochondrial disorders.
    Chinnery P; Majamaa K; Turnbull D; Thorburn D
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004426. PubMed ID: 16437486
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis.
    Kennedy C; Köller Y; Surkova E
    Atherosclerosis; 2020 Apr; 299():1-8. PubMed ID: 32179207
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chronic treatment with coenzyme Q10 reverses restraint stress-induced anhedonia and enhances brain mitochondrial respiratory chain and creatine kinase activities in rats.
    Aboul-Fotouh S
    Behav Pharmacol; 2013 Oct; 24(7):552-60. PubMed ID: 23928691
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mitochondria-targeted therapy rescues development and quality of embryos derived from oocytes matured under oxidative stress conditions: a bovine in vitro model.
    Marei WFA; Van den Bosch L; Pintelon I; Mohey-Elsaeed O; Bols PEJ; Leroy JLMR
    Hum Reprod; 2019 Oct; 34(10):1984-1998. PubMed ID: 31625574
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Coenzyme Q10: its biosynthesis and biological significance in animal organisms and in humans].
    Siemieniuk E; Skrzydlewska E
    Postepy Hig Med Dosw (Online); 2005; 59():150-9. PubMed ID: 15928598
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Packaging of the Coenzyme Q
    Yamada Y; Burger L; Kawamura E; Harashima H
    Biol Pharm Bull; 2017; 40(12):2183-2190. PubMed ID: 29199241
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacological advances in mitochondrial therapy.
    Singh A; Faccenda D; Campanella M
    EBioMedicine; 2021 Mar; 65():103244. PubMed ID: 33647769
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia.
    Schapira AH
    Biochim Biophys Acta; 1999 Feb; 1410(2):159-70. PubMed ID: 10076024
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
    Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
    Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Coenzyme Q10 supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials.
    Akbari A; Mobini GR; Agah S; Morvaridzadeh M; Omidi A; Potter E; Fazelian S; Ardehali SH; Daneshzad E; Dehghani S
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1483-1499. PubMed ID: 32583356
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials.
    Qu H; Meng YY; Chai H; Liang F; Zhang JY; Gao ZY; Shi DZ
    Eur J Med Res; 2018 Nov; 23(1):57. PubMed ID: 30414615
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
    Cook A; Boesch S; Heck S; Brunt E; Klockgether T; Schöls L; Schulz A; Giunti P
    Acta Neurol Scand; 2019 Jun; 139(6):533-539. PubMed ID: 30887496
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Coenzyme Q
    Raizner AE; Quiñones MA
    J Am Coll Cardiol; 2021 Feb; 77(5):609-619. PubMed ID: 33538259
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure.
    Rosenfeldt F; Hilton D; Pepe S; Krum H
    Biofactors; 2003; 18(1-4):91-100. PubMed ID: 14695924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.